Patrick Baeuerle

Patrick A. Baeuerle is the founder of Maverick Therapeutics, Inc., founded in 2016.
Dr. Baeuerle is the founder of Werewolf Therapeutics, Inc., founded in 2017.
Dr. Baeuerle is the founder of iOmx Therapeutics AG, founded in 2016.
Dr. Baeuerle was the founder of Harpoon Therapeutics, Inc., founded in 2015, and served as Director from 2016 to 2020.
Dr. Baeuerle was the founder of TCR² Therapeutics, Inc., founded in 2015, and served as Independent Director from 2015 to 2021.
Dr. Baeuerle was the founder of Cullinan Oncology LLC, founded in 2016, and served as Chief Scientific Officer-Biologics from 2016 to 2022.
Dr. Baeuerle was the founder of Cullinan Therapeutics, Inc., founded in 2016, and served as Chief Scientific Officer from 2022 to 2023.
Dr. Baeuerle is also the founder of Crossbow Therapeutics, Inc...
Dr. Baeuerle is currently Director at TeGenero AG since 2009.
Dr. Baeuerle is Executive Partner at MPM BioImpact LLC since 2015.
Dr. Baeuerle is a Member of the European Molecular Biology Organization.
Formerly, Dr. Baeuerle was Chairman-Biochemistry & Professor at the University of Freiburg from 1994 to 1996.
Dr. Baeuerle was Director-Drug Discovery at Tularik, Inc. from 1996 to 1998.
Dr. Baeuerle was Head-Global Business at F.
Hoffmann-La Roche Ltd. from 1998 to 2000.
Dr. Baeuerle was Chief Scientific Officer at Micromet AG from 1998 to 2012.
Dr. Baeuerle was Vice President-Research & General Manager at Amgen Research (Munich) GmbH from 2012 to 2015.
Dr. Baeuerle was Chief Scientific Officer & Senior Vice President at Amgen Rockville, Inc. from 1998 to 2012.
Education includes a doctorate from Max-Planck-Institute for Molecular Genetics.
Dr. Baeuerle earned undergraduate and doctorate degrees from Ludwig-Maximilians-Universität München in 1987.